Why Is Ascendis Pharma Stock Gaining Friday?

Ascendis Pharma reported positive five-year results from its PaTH Forward trial for TransCon PTH (YORVIPATH), showing sustained efficacy and safety in treating adult hypoparathyroidism. The therapy demonstrated that 82% of patients met composite response endpoints, with 88% maintaining normal calcium levels and 96% achieving independence from active vitamin D therapy. The drug showed durable kidney benefits and a consistent safety profile with no new safety signals. ASND stock rose 3.60% to $223.37 on the news.